Phase
Condition
Lymphoma
Treatment
N/AClinical Study ID
Ages 14-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
patients with confirmed pathological diagnosis of ENKTL as defined by WHO criteria
age 14-80 years
no prior chemotherapy or radiotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
at least one measurable lesion
adequate bone marrow function (i.e. hemoglobin ≥80 g/l, absolute neutrophil count ≥ 1.0 × 10^9/L, platelets ≥ 100 ×10^9/L), adequate renal function (i.e. serum creatinine ≤177 μmol/L), adequate hepatic function (e.g. total bilirubin ≤ two times the upperlimit of normal, and ALT /AST ≤2.5 times the upper limit of normal)
expected survival of more than three months
Exclusion
Exclusion Criteria:
invasion of lymphoma to central nervous system
pre-existing coagulation disorder
other concomitant neoplasms
severe infection
positive HIV antibody
HBV DNA titer higher than 10^4 copies /ml in HBsAg-positive patients post antiviraltherapy
pregnant or lactating women
women of childbearing age unwilling to take contraceptive measures during the studyperiod
Study Design
Connect with a study center
Peking University Cancer Hospital & Institute
Beijing, Beijing 100142
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.